Custom Antibody Market Set for Dynamic Rise with Key Players; Thermo Fisher Scientific Inc.; Abcam plc; Bio-Rad Laboratories, Inc; Creative Biolabs; Merck KGaA
Custom Antibody Market Overview:
The
custom
antibody market is projected to grow at a CAGR of
approximately 10% throughout the forecast period. This expansion is driven by
increasing R&D activity, rising demand for highly specific antibodies,
greater adoption of targeted therapeutics, and continuous advancements in
antibody engineering and production technologies. However, high development
costs and the time-consuming nature of antibody generation continue to pose
challenges that may slow broader market adoption.
Year-End
Mega Sale: Get Up to 10% Off on All Market Research Reports!
Custom antibodies play a critical role in life science
research, clinical diagnostics, and therapeutic development. These
laboratory-engineered antibodies are designed to recognize and bind to specific
antigens that often cannot be targeted effectively using commercially available
alternatives. Their production typically involves steps such as antigen
synthesis, animal immunization (commonly using rabbits, mice, or goats), serum
collection, and purification.
Competitive Landscape Analysis
The global custom antibody market is marked by the
presence of established and emerging market players such as Thermo
Fisher Scientific Inc.; Abcam plc;
Bio-Rad Laboratories, Inc; Creative Biolabs; Merck KGaA; Agilent
Technologies Inc; GenScript; Laboratory Corporation of America; Danaher
Corporation; Kaneka Eurogentec S.A.; Bio-Techne; and Sino Biological,
Inc., among others. Some of the key
strategies adopted by market players include new product development, strategic
partnerships and collaborations, and geographic expansion.
Targeted therapeutics continue to
drive market momentum
A major factor fueling market growth is the rising
emphasis on precision medicine and targeted therapeutics. As research into
complex diseases—such as cancer, autoimmune disorders, and infectious
diseases—advances, scientists increasingly require highly selective antibodies
to detect, study, and manipulate disease-associated proteins. Recent
collaborations underscore this trend. For example, in June 2025, BioNTech and
Bristol Myers Squibb formed a global partnership to co-develop and
commercialize BNT327, BioNTech’s next-generation bispecific PD-L1 × VEGF-A
antibody intended for multiple solid tumor types.
Custom antibodies’ capacity to bind precisely to unique
epitopes enhances diagnostic accuracy and strengthens therapeutic efficacy.
Pharmaceutical and biotechnology companies are investing heavily in custom
antibody development to support the creation of antibody-drug conjugates (ADCs)
and other complex biologics. A notable example occurred in December 2022, when
Merck entered an exclusive licensing and collaboration agreement with
Kelun-Biotech to co-develop seven preclinical ADC candidates for oncology
applications. These advancements continue to broaden the scope and demand for
custom antibodies.
Download Sample Copy: https://meditechinsights.com/custom-antibody-market/request-sample/
Technological innovation and
collaboration enhance custom antibody capabilities
Rapid progress in biotechnology has further solidified
the role of custom antibodies as essential research and clinical tools. Phage
display technology represents one significant advancement, enabling scientists
to screen billions of antibody variants quickly and identify those with optimal
target specificity. Its speed, scalability, and precision have driven
widespread adoption across both industry and academic settings.
Collaborative efforts are also accelerating innovation.
In December 2024, Antibody Solutions became an approved CRO for Levena’s
Singularity™ SAPIEN™ Mouse platform, a transgenic model designed to generate
high-affinity, human-derived antibodies more efficiently for diagnostic and
therapeutic use. Similarly, in March 2024, Sino Biological entered a
partnership with Rapid Novor to integrate Rapid Novor’s REmAb monoclonal
antibody sequencing technology with Sino Biological’s custom antibody
development services—creating a seamless workflow from antibody discovery to
final production.
As technological capabilities expand and collaborative
networks strengthen, the development of high-quality custom antibodies is
becoming more efficient, reproducible, and accessible. These advancements are
lowering entry barriers and enabling broader adoption across research
institutions, diagnostic developers, and biotechnology companies.
Global Custom
Antibody Market Segmentation
This report by Medi-Tech Insights provides the size
of the global custom antibody market at the regional- and country-level
from 2023 to 2030. The report further segments the market based on type,
service, source, application, and end-user.
Market Size & Forecast (2023-2030), By Type, USD
Million
·
Monoclonal
Antibodies
·
Polyclonal
Antibodies
·
Recombinant
Antibodies
·
Others
Market Size & Forecast (2023-2030), By Service, USD
Million
·
Antibody
Development
·
Antibody Production
& Purification
·
Antibody
Fragmentation & Labelling
Market Size & Forecast (2023-2030), By Source, USD
Million
·
Mice
·
Rabbit
·
Others
Market Size & Forecast (2023-2030), By Application,
USD Million
·
Oncology
·
Infectious
Diseases
·
Neurology
·
Stem cells
·
Immunology
·
Cardiovascular
Diseases
·
Others
Market Size & Forecast (2023-2030), By End-user, USD
Million
·
Hospitals
& Clinics
·
Academic
& Research Institutes
·
CRO
·
Others
Market Size & Forecast (2023-2030), By Region, USD
Million
·
North
America
o US
o Canada
·
Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
·
Asia
Pacific
o China
o India
o Japa
o Rest of Asia Pacific
·
Latin
America
·
Middle East
& Africa
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research &
insights firm. Our clients include Fortune 500 companies, blue-chip investors
& hyper-growth start-ups. We have completed 100+ projects in Digital
Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key
demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79

Comments
Post a Comment